CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 174 enrolled
Drug / intervention
ABT-493 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02243280
NCT02243280Phase 2Completed
CompareCT.gov

An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 1, 4, 5, and 6 Infection (SURVEYOR-I)

AbbVie·interventional·Posted Sep 17, 2014·Updated Jul 13, 2021

In Brief

A Phase 2 clinical trial evaluating ABT-493 and ABT-530 for Chronic Hepatitis C and 2 related conditions. Completed, enrolled 174 participants.

Detailed Summary

The purpose of this Phase 2, open-label, 2-part, multicenter study was to evaluate the efficacy, safety, and pharmacokinetics of co-administration of ABT-493 and ABT-530 with and without ribavirin (RBV) at different doses in chronic Hepatitis C virus (HCV) Genotype 1 (GT1), Genotype 4 (GT4), Genotype 5 (GT5), and Genotype 6 (GT6) infection with compensated cirrhosis (GT1 only) or without cirrhosis (GT1, GT4, GT5, or GT6). Although RBV was initially planned in the protocol, it was not administered in any of the study arms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C, Hepatitis C Virus, HCV
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 17, 2014
Enrollment StartAug 1, 2014
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.8 years ago

Interventions

ABT-493drug

Tablet

ABT-530drug

Tablet